If you can't view this video, your browser does not support HTML5 videos
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).
1 year